Low Dose GLP-1 After Reaching Goal Weight: What the Evidence Shows

You have reached your goal weight. Now comes the harder question: what happens next?

You could stop the medication and see if the results stick. Many patients try this. Most of them regain the weight within a year. Or you could stay on a lower maintenance dose – enough to keep the appetite signal turned down, without the side effects of active treatment dosing.

The evidence is clear about what stopping does. The evidence on staying long-term at a lower dose is reassuring, though not complete. This guide walks through what the research shows and what it means for your situation.

The STEP 4 data: Why stopping usually does not work

The STEP 4 trial (published in JAMA in 2021)^[1] followed patients who completed 68 weeks of active semaglutide treatment and then did one of two things.

Half the group stopped the medication. Over the next year, they regained about 67 percent of the weight they had lost. That is not a failure of willpower or discipline. That is biology. When the GLP-1 signal is removed, your appetite and digestion return to their baseline. For most people, that baseline still favors weight gain.

The other half continued semaglutide at the same dose they had been taking. They regained almost none of their weight.

This trial established the case for continued medication. It did not establish whether continuing at a lower dose would work the same way. That evidence comes from two other studies.

Tirzepatide maintenance: SURMOUNT-4

The SURMOUNT-4 trial^[2] looked at patients on tirzepatide (GLP-1/GIP agonist) who reached goal weight and then were randomized to either continue or stop.

The group that continued maintained their results. The group that stopped regained weight. This replicated the STEP 4 finding with a different medication in the same drug class.

Neither trial specifically studied “microdosing” (much lower doses for maintenance). But the principle is sound: the medication works by restoring appetite control. Lower doses provide partial restoration, which may be enough to maintain weight without the side effects of full therapeutic dosing.

Long-term safety: The SELECT trial (5 years)

The best long-term safety data available for GLP-1 medications comes from the SELECT trial^[3], which followed 17,604 patients on semaglutide for up to 5 years (published in the New England Journal of Medicine in 2023).

Key findings:

No new safety signals emerged over 5 years. The side effect profile at therapeutic dose (2.4mg weekly) remained consistent with what was observed in shorter trials. Adverse events like nausea and vomiting were more common early in treatment and decreased over time as patients adapted.

Patients who continued semaglutide showed cardiovascular benefit (reduced heart attack and stroke risk), which persisted throughout the 5-year observation period.

The LEADER trial in earlier GLP-1s (liraglutide, a different medication in the class) showed similar long-term safety over 3.1 years with no emerging risks.

What this means: The longest safety data we have is 5 years in nearly 18,000 patients. We do not have data on 10+ year use at any dose because this generation of medications has not been used for that long. But 5 years is meaningful, and it shows the medication to be safe and well-tolerated over that period.

What “low dose” maintenance actually means

There is no FDA-approved “maintenance dose” for GLP-1 weight management medications. The only FDA-approved doses are the therapeutic doses used in clinical trials. Semaglutide goes up to 2.4mg weekly for weight loss. Tirzepatide goes up to 15mg weekly.

Low-dose or microdose maintenance is an individualized clinical decision. It means finding the lowest dose that maintains your weight loss results with acceptable side effect burden.

In practice, maintenance doses for GLP-1s typically range from 30 to 70 percent of the maximum therapeutic dose. For semaglutide, that translates to 0.5mg to 1.7mg weekly. For tirzepatide, roughly 3mg to 10mg weekly. Your provider will work with you to find the dose that keeps you stable without unwanted side effects.

The Microdose program offers a $199/month all-inclusive plan designed around this principle: lower, maintenance-level dosing for patients who have already reached their goal and now need ongoing support.

Why staying on low-dose maintenance makes sense

Weight maintenance: This is the primary purpose. The STEP 4 and SURMOUNT-4 trials showed that continuing the medication keeps weight off. Lower doses appear to accomplish this in most patients, based on clinical experience and the logic of the mechanism.

Metabolic benefits persist: Many of the metabolic improvements that happen during active weight loss (lower blood pressure, better glucose control, improved lipid profile) persist as long as you maintain the weight loss. The low maintenance dose supports the weight maintenance, which in turn supports the metabolic improvements.

Reduced food noise: Even at lower doses, GLP-1 medications provide appetite support and reduce the mental urge to eat. Many patients on maintenance dosing report that this benefit alone is worth the cost and the commitment to staying on medication.

Cardiovascular benefit potential: The SELECT trial showed cardiovascular benefit at therapeutic doses. Whether lower maintenance doses provide the same benefit has not been directly studied. It is plausible that the weight maintenance itself drives much of the benefit, but this remains an area of active research.

What to consider before staying on maintenance

Cost: The Microdose program is designed to be affordable at $199/month, covering medication, provider care, labs, and coaching. This is significantly less than the cost of active treatment dosing because you are using less medication. But it is still an ongoing cost. Compare this to the cost of regaining weight and the health costs that follow.

Side effects: At lower doses, GLP-1 side effects are usually minimal. Many patients on microdose maintenance experience few or no ongoing side effects beyond what they adapted to during active treatment. But individual experience varies. Nausea, constipation, and reduced appetite can persist, and they can affect quality of life. This is a conversation to have with your provider.

Duration of commitment: There is no clinical consensus on how long you should stay on low-dose maintenance. Some patients continue indefinitely. Others taper and discontinue after a period of time. Some take breaks and re-start if regain begins. None of these approaches has been formally studied. The choice depends on your goals, your biology, and your provider’s assessment of what keeps you stable.

Bone and muscle health: GLP-1 medications can affect bone mineral density and muscle mass, especially during active weight loss at therapeutic doses. During a maintenance phase at lower doses, this effect appears to be slower or minimal. But annual lab work and discussion with your provider about strength training and nutrition remain important to preserve bone and muscle long-term.

The “blood pressure medication” analogy

Some providers frame long-term low-dose GLP-1 maintenance by comparing it to blood pressure medication.

Obesity and metabolic dysfunction are chronic conditions. They do not “get cured” by reaching a goal weight. The underlying biological drivers of appetite and metabolism persist. Just as blood pressure remains elevated after you stop blood pressure medication, appetite and weight-gain biology remain elevated after you stop GLP-1 medication.

If you take blood pressure medication indefinitely at the lowest effective dose, you are making a rational choice about managing a chronic condition. The same logic applies to low-dose GLP-1 maintenance.

This is a useful analogy for thinking about the decision. But it is not clinical equivalence. The evidence base, approval status, side effect profiles, and duration of use differ between the two classes of drugs. The analogy is useful as a mental model; it should not replace a conversation with your provider about your specific situation.

Who this approach works well for

Low-dose maintenance is a good fit if:

You have reached your goal weight on active treatment and want to transition to a lower dose rather than stop entirely. You do not want to risk the regain that STEP 4 showed is likely if you discontinue.

You experienced significant weight regain in the past when you stopped weight loss medications or programs. You want to avoid that cycle again.

Your provider determines that ongoing low-dose treatment is clinically appropriate for your health history and current status. This is the key decision-maker.

You can afford the $199/month all-inclusive cost or can use FSA/HSA benefits to cover it. Cost is a legitimate barrier, and you should discuss affordability with your provider.

What the long-term data says vs. what we do not yet know

What we know:

• Stopping GLP-1 leads to weight regain in most patients (STEP 4, SURMOUNT-4).
• Continuing the medication maintains weight loss.
• Semaglutide is safe and well-tolerated over 5 years at therapeutic doses.
• Lower doses are used clinically with apparent good safety, though formal long-term data at microdose ranges does not exist.

What we do not know:

• Whether lower maintenance doses have the same long-term safety profile as therapeutic doses (they likely do, but specific data is limited).
• Whether lower maintenance doses provide the same cardiovascular benefits as therapeutic doses (probably some benefit, but not formally studied).
• The appropriate duration of maintenance dosing for any individual patient (this varies by person and is a provider decision).
• Long-term outcomes beyond 5 years (this data will come from ongoing studies and real-world experience over time).

This is not a weakness of the evidence. It is a reflection of the fact that these medications are relatively new for weight management, and the long-term research is still being conducted. What we know is reassuring. What we do not yet know is not disqualifying.

Next steps

If you have reached your goal weight and are considering the Microdose maintenance program, the next step is a conversation with an independent, licensed provider.

Complete the free online assessment on this site. Provide your health history, current weight and goal, and any questions you have about staying on medication long-term. An independent provider will review your information and determine whether the Microdose program is clinically appropriate for your situation.

If it is appropriate, your provider will prescribe a maintenance dose, and your medication will be prepared by a US-based, state-licensed compounding pharmacy and shipped to your door. Your all-inclusive fee covers the medication, your monthly check-in with your provider, any required lab work, and access to our medical weight loss coaching.

You are not locked in. You can adjust your dose, pause, or discontinue at any time based on how you are doing. This is an option to maintain your results, not a commitment to stay on it forever.

Citations

[1] Rubino DM, et al. “Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults.” JAMA 2021;325(14):1414-1425. https://pubmed.ncbi.nlm.nih.gov/33755728/

[2] Aronne LJ, et al. “Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.” JAMA. 2024;331(1):38-48. https://pubmed.ncbi.nlm.nih.gov/38078870/

[3] Lincoff AM, et al. “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.” New England Journal of Medicine 2023;389(21):2221-2232. https://pubmed.ncbi.nlm.nih.gov/37952131/